Nasdaq5d
Sagimet Biosciences Announces IND Clearance for TVB-3567, a Second FASN Inhibitor Targeting Acne, with Phase 1 Trial Planned for 2025
Sagimet Biosciences cleared an IND for TVB-3567, a FASN inhibitor for acne, with Phase 1 trials planned for 2025. Sagimet Biosciences Inc. announced the clearance of its Investigational New Drug ...
Business Insider5d
Sagimet Biosciences announces clearance of IND for FASN inhibitor TVB-3567
Sagimet Biosciences (SGMT) announced the clearance of its Investigational New Drug, IND, application for TVB-3567, the Company’s second fatty acid synthase, FASN, inhibitor. TVB-3567 is a potent ...
Business Insider5d
Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne
TVB-3567 is the Company’s second fatty acid synthase (FASN) inhibitor First-in-human Phase 1 trial initiation planned in 2025 SAN MATEO, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Sagimet ...
Morningstar5d
Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne
TVB-3567 is a potent and selective small molecule FASN inhibitor, planned to enter clinical development for the treatment of acne. The IND with the U.S. Food and Drug Administration’s Division ...